8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON D.C. 20549

____________

FORM 8‑K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 26, 2011

The Medicines Company

(Exact Name of Registrant as Specified in Charter)

Delaware	000-31191	04-3324394
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8 Sylvan Way Parsippany, New Jersey	07054
(Address of Principal Executive Offices)	(Zip Code)

Registrant's telephone number, including area code: (973) 290-6000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 26, 2011, the Board of Directors of The Medicines Company (the “Company”) elected Glenn P. Sblendorio, Executive Vice President and Chief Financial Officer of the Company, to serve as a director, effective immediately. Mr. Sblendorio joined the Board as a Class 3 Director and is scheduled to stand for re-election as a director at the Company's 2012 annual meeting of stockholders.

A copy of the press release containing the announcement is included as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits

(c)Exhibits

99.1Press release dated July 28, 2011

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

THE MEDICINES COMPANY

Date:  July 28, 2011By:/s/ Paul M. Antinori

Paul M. Antinori

Senior Vice President and General Counsel

Exhibit Index

Exhibit No.	Description
99.1	Press release dated July 28, 2011

EX-99.1

Exhibit 99.1

Contact: Michael Mitchell

The Medicines Company

973-290-6000

investor.relations@themedco.com

FOR IMMEDIATE RELEASE:

The MEDICINES COMPANY APPOINTS GLENN P. SBLENDORIO TO BOARD OF DIRECTORS

PARSIPPANY, NJ - July 28, 2011 - The Medicines Company (NASDAQ: MDCO) today announced the appointment of Glenn Sblendorio to the Company's Board of Directors. Mr. Sblendorio has been Chief Financial Officer and Executive Vice President of The Medicines Company since 2006.

“Glenn has been a valued member of our leadership team and as a Director, I am confident he will bring the same strategic thinking and global vision to the Board as he has brought to the business over the last five years. Our focus continues to be delivering leading hospital medicines to the marketplace,“ said Clive Meanwell, Chairman and CEO.

Prior to joining the organization, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. until it was acquired by OSI Pharmaceuticals, Inc. in November 2005. From July 2000 to February 2002, Mr. Sblendorio served as Senior Vice President of Business Development for the Company. From 1998 to July 2000, he was the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. Mr. Sblendorio's pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions, including Chief Financial Officer of Roche Molecular Systems and Head of Finance-Controller for Amgen/Roche Europe. Mr. Sblendorio received his B.B.A. in accounting from Pace University and his M.B.A. in Finance from Fairleigh Dickinson University.

About The Medicines Company

The Medicines Company (NASDAQ: MDCO) provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well being of critically ill patients. The Medicines Company's website is www.themedicinescompany.com.

The Medicines Company 8 Sylvan Way Parsippany, New Jersey 07054     Tel: (973)290-6000 Fax: (973)656-9898